EROX — Human Pheromone Sciences Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeMicro Cap

Annual income statement for Human Pheromone Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2006 December 31st	2007 December 31st	2008 December 31st	2009 December 31st	2010 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10KSB	10KSB	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1.23	1.29	0.992	0.885	0.806
Cost of Revenue
Gross Profit	0.94	0.915	0.67	0.69	0.678
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	1.36	1.37	1.26	1.17	0.901
Operating Profit	-0.131	-0.076	-0.266	-0.286	-0.095
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-0.104	-0.011	-0.236	-0.283	-0.095
Provision for Income Taxes
Net Income After Taxes	-0.111	-0.016	-0.239	-0.284	-0.097
Net Income Before Extraordinary Items
Net Income	-0.111	-0.016	-0.239	-0.284	-0.097
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-0.111	-0.016	-0.239	-0.284	-0.097
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.027	-0.004	-0.058	-0.068	-0.023
Dividends per Share